Anxioselective anxiolytics: Can less be more?

European Journal of Pharmacology

Volumn 500, Issue 1-3 SPEC. ISS., 2004, Pages 441-451

  Basile, Anthony S ^a   Lippa, Arnold S ^a   Skolnick, Phil ^a  

^a DOV Pharmaceutical Inc   (United States)

Author keywords

Aminobutyric acid A; Anxiolytic; Benzodiazepine

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 6 FLUORO 2,9 DIHYDRO 9 METHYL 2 PHENYL 4 (1 PYRROLIDINYLCARBONYL) 1H PYRIDO[3,4 B]INDOL 1 ONE; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ABECARNIL; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BRETAZENIL; CARBOLINE DERIVATIVE; DIAZEPAM; FLUNITRAZEPAM; OCINAPLON; PARTIAL AGONIST; PYRIDONE DERIVATIVE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

AMNESIA; ANXIETY DISORDER; ATAXIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; GABAERGIC TRANSMISSION; HUMAN; MOLECULAR GENETICS; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BENZODIAZEPINONES; CARBOLINES; CLINICAL TRIALS; FLUOROBENZENES; HUMANS; INDOLES; PYRROLES; QUINOLONES; RECEPTORS, GABA-A; TRIAZOLES;

EID: 4644304934     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.07.043     Document Type: Review

References (96)

1. S. Arbilla, H. Depoortere, P. George, and S.Z. Langer Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats Naunyn-Schmiedeberg's Arch. Pharmacol. 330 1985 248 251
2. A receptor benzodiazepine binding site Curr. Drug Targets. CNS Neurol. Disord. 2 2003 213 232
3. J.C. Ballenger, S. McDonald, R. Noyes, K. Rickels, N. Sussman, S. Woods, J. Patin, and J. Singer The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder Psychopharmacol. Bull. 27 1991 171 179
4. A receptors: classification on the basis of subunit structure and receptor function Pharmacol. Rev. 50 1998 291 313
5. A receptor modulator, in generalized anxiety Abstr.-Soc. Neurosci. 396 2002 15
6. 1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice Behav. Pharmacol. 11 2000 125 131
7. A receptors rendered diazepam-insensitive by point-mutated alpha-subunits FEBS Lett. 431 1998 400 404
8. A alpha 5 receptor inverse agonist which enhances cognition J. Med. Chem. 46 2003 2227 2240
9. K. Chilman-Blair, J. Castaner, and J.S. Silvestre Ocinaplon Drugs Future 28 2003 115 120
10. A receptor-ion channels J. Med. Chem. 45 2002 1887 1900
11. A receptor J. Neurosci. 22 2002 5572 5580
12. 1 receptor subtype specific antagonist Med. Chem. Res. 5 1995 710 718
13. A receptor clustering results in enhanced anxiety and a bias for threat cues Nat. Neurosci. 2 1999 833 839
14. F. Crestani, J.R. Martin, H. Möhler, and U. Rudolph Mechanism of action of the hypnotic zolpidem in vivo Br. J. Pharmacol. 131 2000 1251 1254
15. F. Crestani, K. Low, R. Keist, M. Mandelli, H. Möhler, and U. Rudolph Molecular targets for the myorelaxant action of diazepam Mol. Pharmacol. 59 2001 442 445
16. A receptors Proc. Natl. Acad. Sci. U. S. A. 99 2002 8980 8985
17. P. Czobor, J. Stark, G. Beer, S. Beckett, B. Dietrich, A. Lippa, and B. Beer A double-blind, placebo controlled study of DOV 273,547 (Ocinaplon) in the treatment of generalized anxiety disorder (GAD) Abstr.-Soc. Neurosci. 959 2003 12
18. P. Czobor, J. Stark, G. Beer, F. Duncanson, P. Skolnick, A. Lippa, and B. Beer Ocinaplon: a new anxio-selective agent in patients with GAD Am. Psychiatr. Assoc. 2004 526
19. A receptors different from zolpidem, zopiclone and benzodiazepines Neurosci. Res. Commun. 25 1999 139 148
20. J.R.T. Davidson Pharmacotherapy of generalized anxiety disorder J. Clin. Psychiatry 62 Suppl. 11 2001 46 50
21. 2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic J. Pharmacol. Exp. Ther. 303 2002 777 790
22. T. Duka, B. Schutt, W. Krause, R. Dorow, S. McDonald, and K. Fichte Human studies on abecarnil a new beta-carboline anxiolytic: safety, tolerability and preliminary pharmacological profile Br. J. Clin. Pharmacol. 35 1993 386 394
23. M. Facklam, P. Schoch, E.P. Bonetti, F. Jenck, J.R. Martin, J.L. Moreau, and W.E. Haefely Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies J. Pharmacol. Exp. Ther. 261 1992 1113 1121
24. J.M. Gorman, and J.M. Kent SSRIs and SMRIs: broad spectrum of efficacy beyond major depression J. Clin. Psychiatry 60 Suppl. 4 1999 33 38
25. A receptor subtypes Eur. Neuropsychopharmacol. 6 1996 119 125
26. P.E. Greenberg, T. Sisitsky, R.C. Kessler, S.N. Finkelstein, E.R. Berndt, J.R.T. Davidson, J.C. Ballenger, and A.J. Fyer The economic burden of anxiety disorders in the 1990s J. Clin. Psychiatry 60 1999 427 435
27. G. Griebel Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82 1999 1 61
28. G. Griebel, G. Perrault, V. Letang, P. Granger, P. Avenet, H. Schoemaker, and D.J. Sanger New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes Psychopharmacology (Berl.) 146 1999 205 213
29. G. Griebel, G. Perrault, S. Tan, H. Schoemaker, and D.J. Sanger Comparison of the pharmacological properties of classical and novel BZ-omega receptor ligands Behav. Pharmacol. 10 1999 483 495
30. A receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms CNS Drug Rev. 9 2003 3 20
31. W. Haefely Pharmacological profile of two benzodiazepine partial agonists: Ro 16-6028 and Ro 17-1812 Clin. Neuropharmacol. 7 Suppl. 1 1984 670 671
32. 2 subunit of the γ-aminobutyrate type A receptor Neuropharmacology 38 1999 253 265
33. T.B.C. Johnstone, D.J. Hogenkamp, L. Coyne, J. Su, R.F. Halliwell, M.B. Tran, R.F. Yoshimura, W.-Y. Li, J. Wang, and K.W. Gee Modifying quinoline antibiotics yields new anxiolytics Nat. Med. 10 2004 31 32
34. G.H. Jones, C. Schneider, H.H. Schneider, J. Seidler, B.J. Cole, and D.N. Stephens Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies Psychopharmacology (Berl) 114 1994 191 199
35. A1 receptors in the ventral pallidum Neuropsychopharmacology 28 2003 2124 2137
36. A receptor subtypes J. Pharmacol. Exp. Ther. 266 1993 385 391
37. A receptors Prog. Neurobiol. 67 2002 113 159
38. A receptor delta subunit-deficient mice: recruitment of gamma 2 subunits Neuroscience 109 2002 733 743
39. A receptor by ocinaplon, an anxioselective pyrazolopyrimidine Soc. Neurosci. 48 2003 3
40. 1 subunit knockout mice J. Pharmacol. Exp. Ther. 302 2002 1037 1045
41. A receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem Neuropharmacology 43 2002 685 694
42. M. Krawcyzk, P. Popik, D. Francis, J. Winslow, D. Helton, J. Sharp, D. Fick, D. Dow-Edwards, J. Tizzano, A. Lippa, A. Basile, and P. Skolnick Ocinaplon: activity in animal models predictive of anxiolysis Soc. Biol. Psychiatry Abstr. 2004 762
43. A receptor-channel complex expressed in human kidney cell lines Brain Res. 631 1993 143 146
44. A receptor subunit mRNAs in the rat brain: III. Embryonic and postnatal development J. Neurosci. 12 1992 4151 4172
45. A.S. Lippa, J. Coupet, E.N. Greenblatt, C.A. Klepner, and B. Beer A synthetic non-benzodiazepine ligand for benzodiazepine receptors: a probe for investigating neuronal substrates of anxiety Pharmacol. Biochem. Behav. 11 1979 99 106
46. A.S. Lippa, P.A. Nash, and E.N. Greenblatt Pre-clinical neuro-psychopharmacological testing procedures for anxiolytic drugs S. Fielding H. Lal Anxiolytics: Industrial Pharmacology vol. 3 1979 Futura Publishing Mt. Kisco, NY 41 81
47. A.S. Lippa, L.R. Meyerson, and B. Beer Molecular substrates of anxiety: clues from the heterogeneity of benzodiazepine receptors Life Sci. 31 1982 1409 1417
48. K. Low, F. Crestani, R. Keist, D. Benke, I. Brunig, J.A. Benson, J.-M. Fritschy, T. Rulicke, H. Bluethmann, H. Möhler, and U. Rudolph Molecular and neuronal substrates for the selective attenuation of anxiety Science 290 2000 131 134
49. H. Lüddens, P.H. Seeburg, and E.R. Korpi Impact of β and γ variants on ligand-binding properties of γ-aminobutyric acid type A receptors Mol. Pharmacol. 45 1994 810 814
50. J.R. Martin, L. Pieri, E.P. Bonetti, R. Schaffner, W.P. Burkard, R. Cumin, and W.E. Haefely Ro 16-6028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor Pharmacopsychiatry 21 1988 360 362
51. J.R. Martin, P. Schoch, F. Jenck, J.L. Moreau, and W.E. Haefely Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero Psychopharmacology 111 1993 415 422
52. C. McCabe, D. Shaw, J.R. Atack, L.J. Street, K.A. Wafford, G.R. Dawson, D.S. Reynolds, and J.C. Leslie Subtype-selective GABAergic drugs facilitate extinction of mouse operant behavior Neuropharmacology 46 2004 171 178
53. A-receptor subtypes really occur in the brain? Trends Neurosci. 19 1996 139 143
54. 1 subtype Nat. Neurosci. 3 2000 587 592
55. A receptor-mediated currents: lack of subunit specificity Eur. J. Pharmacol. 268 1994 209 214
56. M.J. Millan, M. Brocco, A. Gobert, G. Dorey, P. Casara, and A. Dekeyne Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent Neuropsychopharmacology 25 2001 585 600
57. F. Minier, and E. Sigel Positioning of the γ-subunit isoforms confers a functional signature to γ-aminobutyric acid type A receptors Proc. Natl. Acad. Sci. U. S. A. 101 2004 7769 7774
58. H. Möhler, and T. Okada Benzodiazepine receptor: demonstration in the central nervous system Science 198 1977 849 851
59. A receptor determined by electron microscopic image analysis J. Neurochem. 62 1994 815 818
60. M. Ozawa, K. Sugimachi, Y. Nakada-Kometani, T. Akai, and M. Yamaguchi Chronic pharmacological activities of the novel anxiolytic beta-carboline abecarnil in rats J. Pharmacol. Exp. Ther. 269 1994 457 462
61. A.C. Pande, J.G. Crockatt, D.E. Feltner, C.A. Janney, W.T. Smith, R. Weisler, P.D. Londborg, R.J. Bielski, D.L. Zimbroff, J.R.T. Davidson, and M. Liu-Dumaw Pregabalin in generalized anxiety disorder: a placebo-controlled trial Am. J. Psychiatry 160 2003 533 540
62. M.H. Pollack, J.J. Worthington, G.G. Manfro, M.W. Otto, and B.G. Zucker Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone J. Clin. Psychiatry 58 Suppl. 11 1997 19 23
63. M.H. Pollack, R. Zaninelli, A. Goddard, J.P. McCafferty, K.M. Bellew, D.B. Burnham, and M.K. Iyengar Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial J. Clin. Psychiatry 62 2001 350 357
64. A receptor subtypes Psychopharmacol. Ser. 11 1993 50 61
65. A receptor subunit for benzodiazepine pharmacology Nature 338 1989 582 585
66. A receptor subtype is involved? Trends Pharmacol. Sci. 22 2001 402 403
67. L.A. Riblet, D.P. Taylor, M.S. Eison, and H.C. Stanton Pharmacology and neurochemistry of buspirone J. Clin. Psychiatry 43 1982 11 18
68. D.P. Rice, and L.S. Miller Health economics and cost implications of anxiety and other mental disorders in the United States Br. J. Psychiatry 173 Suppl. 34 1998 4 9
69. A receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics Annu. Rev. Pharmacol. Toxicol. 44 2004 475 498
70. A receptor subtypes: dissecting their pharmacological functions Trends Pharmacol. Sci. 22 2001 188 194
71. B. Saletu, J. Grunberger, and L. Linzmayer On the central effects of a new partial benzodiazepine agonist Ro 16-6028 in man: pharmaco-EEG and psychometric studies Int. J. Clin. Pharmacol. Ther. Toxicol. 27 1989 51 65
72. J.J. Sandford, V.A. Spilios, and D.J. Nutt The psychobiology of anxiolytic drugs: Part 1. Basic neurobiology Pharmacol. Ther. 88 2000 197 212
73. D.D. Schoepp, D.E. Jane, and J.A. Monn Pharmacological agents acting at subtypes of metabotropic glutamate receptors Neuropharmacology 38 1999 1431 1476
74. H.E. Shannon, F. Guzman, and J.M. Cook β-Carboline-3-carboxylate-t- butyl ester: a selective BZ1 benzodiazepine receptor antagonist Life Sci. 35 1984 2227 2236
75. A receptor subtypes Curr. Top. Med. Chem. 2 2002 795 816
76. P. Skolnick Is receptor heterogeneity relevant to the anxiolytic actions of benzodiazepine receptor ligands? M. Briley S.E. File New Concepts in Anxiety 1991 Macmillan London 190 203
77. A receptors containing alpha-5 subunits J. Pharmacol. Exp. Ther. 283 1997 488 493
78. 36Cl ion flux Mol. Pharmacol. 59 2001 1108 1118
79. R.F. Squires, D.I. Benson, C. Braestrup, J. Coupet, C.A. Klepner, V. Myers, and B. Beer Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors Pharmacol. Biochem. Behav. 10 1979 825 830
80. R. Squires, and C. Braestrup Benzodiazepine receptors in rat brain Nature 266 1977 732 734
81. S.M. Stahl Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder J. Clin. Psychiatry 63 2002 756 757
82. D.N. Stephens, H.H. Schneider, W. Kehr, J.S. Andrews, K.J. Rettig, L. Turski, R. Schmiechen, J.D. Turner, L.H. Jensen, E.N. Petersen, T. Honore, and J.B. Hansen Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors J. Pharmacol. Exp. Ther. 253 1990 334 343
83. D.N. Stephens, L. Turski, G.H. Jones, K.G. Steppuhn, and H.H. Schneider Abecarnil: a novel anxiolytic with mixed full agonist/partial agonist properties in animal models of anxiety and sedation Psychopharmacol. Ser. 11 1993 79 95
84. The American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th Edition, Text Revision 2000 American Psychiatric Association Washington, DC 429 484
85. A receptor subtype J. Neurosci. 17 1997 2728 2737
86. L. Turski, D.N. Stephens, L.H. Jensen, E.N. Petersen, B.S. Meldrum, S. Patel, J.B. Hansen, W. Loscher, H.H. Schneider, and R. Schmiechen Anticonvulsant action of the beta-carboline abecarnil: studies in rodents and baboon, Papio papio J. Pharmacol. Exp. Ther. 253 1990 344 352
87. E.H. Uhlenhuth, M.B. Balter, T.A. Ban, and K. Yang International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders J. Clin. Psychopharmacol. 19 1999 23S 29S
88. A.L. van Steveninck, R. Gieschke, R.C. Schoemaker, G. Roncari, B. Tuk, M.S. Pieters, D.D. Breimer, and A.F. Cohen Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol Br. J. Clin. Pharmacol. 41 1996 565 573
89. I. Varia, and F. Rauscher Treatment of generalized anxiety disorder with citalopram Int. Clin. Psychopharmacol. 17 2002 103 107
90. K.E. Vanover, L. Zhang, and J.E. Barrett Discriminative stimulus and anxiolytic-like effects of the novel compound CL 273,547 Exp. Clin. Psychopharmacol. 2 1994 223 233
91. 2 subunit FEBS Lett. 313 1992 113 117
92. A/benzodiazepine receptors Mol. Pharmacol. 44 1993 437 442
93. 2 phosphorylation site Proc. Natl. Acad. Sci. U. S. A. 87 1990 9966 9970
94. A receptors is essential for benzodiazepine agonist binding J. Biol. Chem. 267 1992 1426 1429
95. A receptor subunit mRNAs in the rat brain: I. Telencephalon, diencephalon, mesencephalon J. Neurosci. 12 1992 1040 1062
96. H.U. Wittchen, and J. Hoyer Generalized anxiety disorder: nature and course J. Clin. Psychiatry 62 2001 15 21